

# Recurrence after resection for ductal adenocarcinoma of

World Journal of Surgery

21, 195-200

DOI: 10.1007/s002689900215

Citation Report

#	ARTICLE	IF	CITATIONS
1	Surgical treatment for patients with advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 133-137.	2.0	2
2	Results of surgery and adjuvant radiotherapy for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 143-150.	2.0	25
3	The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 237-242.	1.4	114
4	Pattern of Recurrence after Resection for Intraductal Papillary Mucinous Tumors of the Pancreas. World Journal of Surgery, 1998, 22, 874-878.	0.8	79
6	Ruolo Dell'Endoscopia Nella Palliazione Del Carcinoma Pancreatico. Tumori, 1999, 85, 60-63.	0.6	0
7	General Aspects of Surgical Treatment of Pancreatic Cancer. Digestive Surgery, 1999, 16, 265-275.	0.6	14
8	Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by <sup>111</sup> In-labeled Chimeric Monoclonal Antibody Nd2. Japanese Journal of Cancer Research, 1999, 90, 1179-1186.	1.7	18
9	Are the Results of Pancreatectomy for Pancreatic Cancer Improving?. World Journal of Surgery, 1999, 23, 913-919.	0.8	87
10	Immunotherapy in pancreatic cancer - current status and future. Langenbeck's Archives of Surgery, 1999, 384, 396-404.	0.8	11
11	(Neo)adjuvant treatment in pancreatic cancer—the need for future trials. European Journal of Surgical Oncology, 1999, 25, 132-137.	0.5	5
12	Recommendation for the Examination of Pancreaticoduodenectomy Specimens Removed from Patients with Carcinoma of the Exocrine Pancreas. Digestive Surgery, 1999, 16, 291-296.	0.6	60
13	A prospective study on the prognostic value of cytology and tumour markers (CEA and CA 19-9) in peritoneal washings of patients with periampullary tumours. Hpb, 2000, 2, 75-81.	0.1	1
14	The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. , 2000, 191, 154-161.		131
15	Prognostic factors after surgical resection for pancreatic carcinoma. Journal of Surgical Oncology, 2000, 74, 36-40.	0.8	54
17	Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. European Journal of Surgical Oncology, 2000, 26, 578-582.	0.5	27
18	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, The, 2001, 358, 1576-1585.	6.3	1,019
19	ADJUVANT THERAPY FOR PANCREATIC CANCER. Surgical Clinics of North America, 2001, 81, 667-681.	0.5	14
20	Surgical Treatment for Pancreatic Metastasis From Soft-Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 198-200.	0.6	61

#	ARTICLE	IF	CITATIONS
21	Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. <i>Journal of Gastrointestinal Surgery</i> , 2001, 5, 121-130.	0.9	149
22	NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. <i>British Journal of Cancer</i> , 2001, 84, 864-873.	2.9	68
23	Aktueller Stand multimodaler Therapiekonzepte beim Pankreaskarzinom. <i>Viszeralchirurgie</i> , 2001, 36, 20-28.	0.0	3
25	The role of adjuvant therapy for pancreatic cancer. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 87-107.	1.9	9
26	Regional Targeting Chemoimmunotherapy in Patients Undergoing Pancreatic Resection in an Advanced Stage of Their Disease. <i>Annals of Surgery</i> , 2002, 236, 806-813.	2.1	37
27	Retrovirus-Mediated Herpes Simplex Virus Thymidine Kinase Gene Transfer in Pancreatic Cancer Cell Lines: An Incomplete Antitumor Effect. <i>Pancreas</i> , 2002, 25, e21-e29.	0.5	16
28	The importance of quality assurance in surgical oncology. <i>European Journal of Surgical Oncology</i> , 2002, 28, 571-602.	0.5	34
29	European Adjuvant Trials. , 2002, , 255-267.		0
30	Current and future strategies for combined-modality therapy in pancreatic cancer. <i>Current Oncology Reports</i> , 2002, 4, 202-212.	1.8	8
31	The impact of pylorus-preserving pancreatoduodenectomy on surgical treatment for cancer of the pancreatic head. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 223-232.	2.0	29
32	CT analysis of postoperative tumor recurrence patterns in periampullary cancer. <i>Abdominal Imaging</i> , 2003, 28, 384-391.	2.0	29
33	Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. <i>European Journal of Surgical Oncology</i> , 2003, 29, 721-730.	0.5	28
35	Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. <i>Oncogene</i> , 2004, 23, 2385-2400.	2.6	235
36	Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. <i>Journal of Controlled Release</i> , 2004, 100, 317-330.	4.8	16
37	Is Reporting of Recurrence Data Important in Pancreatic Cancer?. <i>Annals of Surgical Oncology</i> , 2004, 11, 304-309.	0.7	22
38	In situ-formed, tissue-adhesive co-gel composed of styrenated gelatin and styrenated antibody: potential use for local anti-cytokine antibody therapy on surgically resected tissues. <i>Biomaterials</i> , 2004, 25, 5867-5873.	5.7	15
40	Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. <i>British Journal of Surgery</i> , 2004, 91, 1592-1599.	0.1	59
41	Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. <i>Surgical Oncology Clinics of North America</i> , 2004, 13, 567-587.	0.6	26

#	ARTICLE	IF	CITATIONS
42	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1200-1210.	13.9	2,442
43	Clinical Significance of Dihydropyrimidine Dehydrogenase in Adjuvant 5-Fluorouracil Liver Perfusion Chemotherapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2004, 240, 840-844.	2.1	27
44	Terminally Modified Oligodeoxynucleotides Directed Against p53 in an Orthotopic Xenograft Model: A Novel Adjuvant Treatment Strategy for Pancreatic Ductal Carcinoma. <i>Pancreas</i> , 2004, 28, 1-12.	0.5	17
45	Preoperative Detection of Liver Metastases Secondary to Pancreatic Cancer. <i>Pancreas</i> , 2004, 29, 188-192.	0.5	9
46	Resection of a cancer developing in the remnant pancreas after a pancreaticoduodenectomy for pancreas head cancer. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 263-269.	0.9	27
47	Pigment Epithelium-Derived Factor Gene Therapy Inhibits Human Pancreatic Cancer in Mice. <i>Clinical Cancer Research</i> , 2005, 11, 8737-8744.	3.2	63
48	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. <i>Oncogene</i> , 2005, 24, 6626-6636.	2.6	174
49	New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2005, 73B, 203-207.	1.6	14
50	Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. <i>International Journal of Cancer</i> , 2005, 115, 359-367.	2.3	165
51	Prophylactic hepatic irradiation following curative resection of pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2005, 12, 235-242.	2.0	10
52	Metastatic gastric tumor secondary to pancreatic adenocarcinoma. <i>Journal of Gastroenterology</i> , 2005, 40, 209-212.	2.3	20
53	Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration. <i>Journal of Gastroenterology</i> , 2005, 40, 511-517.	2.3	28
54	Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?. <i>Langenbeck's Archives of Surgery</i> , 2005, 390, 94-103.	0.8	89
55	Adjuvant Treatment for Resectable Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4532-4537.	0.8	67
56	Adjuvant 5-FU-Based Chemoradiotherapy for Patients Undergoing R-1/R-2 Resections for Pancreatic Cancer. <i>Digestive Surgery</i> , 2005, 22, 321-328.	0.6	26
57	EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. <i>International Journal of Oncology</i> , 2005, 27, 1321.	1.4	14
58	Intraoperative radiotherapy for patients with carcinoma of the pancreas. <i>Pancreatology</i> , 2005, 5, 438-442.	0.5	12
60	Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. <i>Pancreatology</i> , 2006, 6, 240-247.	0.5	15

#	ARTICLE	IF	CITATIONS
61	Oncological problems in pancreatic cancer surgery. World Journal of Gastroenterology, 2006, 12, 4466.	1.4	59
62	Patterns of Recurrence After Curative Resection of Pancreatic Cancer, Based on Autopsy Findings. Journal of Gastrointestinal Surgery, 2006, 10, 511-518.	0.9	280
63	Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database. Annals of Surgical Oncology, 2006, 13, 1189-1200.	0.7	209
64	Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. International Journal of Colorectal Disease, 2006, 21, 365-372.	1.0	8
65	A Margin-Negative R0 Resection Accomplished With Minimal Postoperative Complications Is the Surgeon's Contribution to Long-Term Survival in Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2006, 10, 1338-1346.	0.9	283
66	Expression of cytokeratin-20 in pancreatic cancer: An indicator of poor outcome after R0 resection. Surgery, 2006, 139, 104-108.	1.0	10
67	Establishment of Perineural Invasion Models and Analysis of Gene Expression Revealed an Invariant Chain (CD74) as a Possible Molecule Involved in Perineural Invasion in Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 2419-2426.	3.2	82
68	Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 267.	3.8	2,144
69	Surgery for Recurrent Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2007, 245, 566-572.	2.1	217
70	Standard resection of pancreatic cancer and the chance for cure. American Journal of Surgery, 2007, 194, S104-S109.	0.9	4
71	Long-term survival after pancreatic cancer treatment. American Journal of Surgery, 2007, 194, S127-S130.	0.9	8
72	Adjuvant chemotherapyâ€”the standard after resection for pancreatic cancer. American Journal of Surgery, 2007, 194, S131-S137.	0.9	3
73	Multimodality Therapy for Pancreatic Cancer. Gastroenterology Clinics of North America, 2007, 36, 391-411.	1.0	1
74	Pancreatic cancer â€” Pathology. Chinese-German Journal of Clinical Oncology, 2007, 6, 95-101.	0.1	1
75	Pancreatic cancer â€” Adjuvant therapy. Chinese-German Journal of Clinical Oncology, 2007, 6, 170-175.	0.1	0
76	Imaging diagnosis of hepatic metastases of pancreatic carcinomas: significance of transient wedge-shaped contrast enhancement mimicking arteriportal shunt. Abdominal Imaging, 2008, 33, 437-443.	2.0	20
77	Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2008, 12, 1664-1673.	0.9	25
78	Long-term outcomes of extended radical resection combined with intraoperative radiation therapy for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 603-607.	2.0	12

#	ARTICLE	IF	CITATIONS
79	A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. <i>Radiation Oncology</i> , 2008, 3, 30.	1.2	6
80	Adjuvant therapy for pancreatic cancer. <i>Cancer</i> , 2008, 112, 243-249.	2.0	62
81	3D Radiotherapy Can Be Safely Combined With Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1438-1446.	0.4	11
82	Neoadjuvant Radiation Is Associated With Improved Survival in Patients With Resectable Pancreatic Cancer: An Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1128-1133.	0.4	85
83	SURGICAL MANAGEMENT OF CARCINOMA OF THE HEAD OF PANCREAS: EXTENDED LYMPHADENECTOMY OR MODIFIED EN BLOC RESECTION?. <i>ANZ Journal of Surgery</i> , 2008, 78, 228-236.	0.3	20
86	Natural History of Pancreatic Cancer Recurrence Following "Curative" Resection in Athymic Mice. <i>Journal of Surgical Research</i> , 2008, 149, 57-61.	0.8	12
87	Neoadjuvant and adjuvant strategies for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 297-305.	0.5	29
88	Perioperative management of pancreatic cancer. <i>Annals of Oncology</i> , 2008, 19, vii273-vii278.	0.6	32
89	Adoptive immunotherapy for pancreatic cancer: Cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. <i>Oncology Reports</i> , 2008, , .	1.2	19
90	Low Serum Level of Cholinesterase at Recurrence of Pancreatic Cancer Is a Poor Prognostic Factor and Relates to Systemic Disorder and Nerve Plexus Invasion. <i>Pancreas</i> , 2008, 36, 241-248.	0.5	31
91	Effective Endovascular Stenting of Malignant Portal Vein Obstruction in Pancreatic Cancer. <i>HPB Surgery</i> , 2009, 2009, 1-5.	2.2	6
92	Neoadjuvant 5 Fluorouracil-Cisplatin Chemoradiation Effect on Survival in Patients with Resectable Pancreatic Head Adenocarcinoma: A Ten-Year Single Institution Experience. <i>Oncology</i> , 2009, 76, 413-419.	0.9	63
93	Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2009, 6, 38-46.	1.7	11
94	Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2009, 394, 249-253.	0.8	28
95	Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 701-711.	1.7	19
96	Surgery for Recurrence of Periapillary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 760-767.	0.9	17
97	Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1mm of a resection margin. <i>Histopathology</i> , 2009, 55, 277-283.	1.6	231
98	Utilization and Determinants of Adjuvant Therapy Among Older Patients Who Receive Curative Surgery for Pancreatic Cancer. <i>Pancreas</i> , 2009, 38, e18-e25.	0.5	43

#	ARTICLE	IF	CITATIONS
99	A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 194-205.	0.7	136
100	The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. <i>Langenbeck's Archives of Surgery</i> , 2010, 395, 451-458.	0.8	125
101	Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 39-45.	1.0	12
102	Elective pancreatic resection – report of a series and review of the literature. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2010, 42, 91-95.	0.3	2
103	Detection of liver metastases secondary to pancreatic cancer: utility of combined helical computed tomography during arterial portography with biphasic computed tomography-assisted hepatic arteriography. <i>Journal of Gastroenterology</i> , 2010, 45, 1241-1246.	2.3	6
104	Tumor Relapse after Pancreatic Cancer Resection is Detected Earlier by 18-FDG PET than by CT. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 131-140.	0.9	78
105	Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma. <i>Gut and Liver</i> , 2010, 4, 384-388.	1.4	13
106	Radiation Therapy in Operable and Locally Advanced Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1022-1031.	2.3	6
107	Repeated Pancreatectomy for Recurrent Pancreatic Carcinoma after Pylorus-Preserving Pancreatoduodenectomy: Report of Two Patients. <i>Case Reports in Gastroenterology</i> , 2010, 4, 429-434.	0.3	17
108	Adjuvant Therapy in Pancreatic Cancer. <i>Digestive Diseases</i> , 2010, 28, 684-692.	0.8	24
109	EUS-guided FNA of local recurrence of pancreatic cancer after surgical resection. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 1076-1080.	0.5	11
110	Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. <i>European Journal of Surgical Oncology</i> , 2010, 36, 987-992.	0.5	57
111	Reoperative Completion Pancreatectomy for Suspected Malignant Disease of the Pancreas. <i>Journal of Surgical Research</i> , 2011, 170, 89-95.	0.8	38
112	The Progression Potential of Peritoneal Dissemination Nodules From Gastrointestinal Tumors. <i>International Surgery</i> , 2011, 96, 352-357.	0.0	3
113	Local recurrence of pancreatic cancer after primary surgical intervention: How to deal with this devastating scenario?. <i>Surgical Oncology</i> , 2011, 20, e133-e142.	0.8	20
114	Perioperative Intra-Arterial and Systemic Chemotherapy for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1110-1115.	0.7	10
115	Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 235-240.	1.4	31
116	Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer through nuclear factor kappa-B inhibition. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 731-739.	1.4	40

#	ARTICLE	IF	CITATIONS
117	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 99-109.	2.0	38
118	Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1026-1034.	0.9	10
119	Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. <i>Radiation Oncology</i> , 2011, 6, 146.	1.2	16
120	Near-Infrared Fluorescence Imaging in Patients Undergoing Pancreaticoduodenectomy. <i>European Surgical Research</i> , 2011, 47, 90-97.	0.6	81
121	Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 432-438.	0.6	0
122	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. <i>Annals of Oncology</i> , 2012, 23, 570-576.	0.6	69
123	Microscopic Margins and Patterns of Treatment Failure in Resected Pancreatic Adenocarcinoma. <i>Archives of Surgery</i> , 2012, 147, 753.	2.3	127
124	The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 469-480.	1.1	10
125	Safety and Optimal Management of Hepatic Arterial Infusion Chemotherapy After Pancreatectomy for Pancreatobiliary Cancer. <i>American Journal of Roentgenology</i> , 2012, 198, 923-930.	1.0	7
126	CXCR4 Expression Predicts Early Liver Recurrence and Poor Survival After Resection of Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e22.	1.3	15
127	Evolving Concepts Regarding the Use of Radiotherapy in the Adjuvant Management of Periapillary Pancreatic Adenocarcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 624-632.	1.0	2
128	Pancreatic Surgery: Beyond the Traditional Limits. <i>Recent Results in Cancer Research</i> , 2012, 196, 53-64.	1.8	9
129	Enhancement of the cytotoxic effects of hypotonic solution using a chloride channel blocker in pancreatic cancer cells. <i>Pancreatology</i> , 2012, 12, 440-448.	0.5	14
130	Radiofrequency Ablation of Liver Metastasis in Patients with Locally Controlled Pancreatic Ductal Adenocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 635-641.	0.2	41
131	Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 574-579.	0.5	72
132	RON is not a prognostic marker for resectable pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 395.	1.1	17
133	Impact of Radiation Therapy Sequence on Survival Among Patients With Resected Pancreatic Head Ductal Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 26-30.	0.7	5
134	Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1696-1704.	0.9	109



#	ARTICLE	IF	CITATIONS
136	Resection margin involvement and tumour origin in pancreatic head cancer. <i>British Journal of Surgery</i> , 2012, 99, 1036-1049.	0.1	140
137	An autopsy study to clarify characteristics of local recurrence after extended pancreatectomy with intraoperative radiation therapy in patients with pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 927-932.	0.8	7
138	Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head?. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 917-925.	0.8	16
139	Fluorescence-Guided Surgery Allows for More Complete Resection of Pancreatic Cancer, Resulting in Longer Disease-Free Survival Compared with Standard Surgery in Orthotopic Mouse Models. <i>Journal of the American College of Surgeons</i> , 2012, 215, 126-135.	0.2	64
140	Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. <i>Pathology International</i> , 2012, 62, 167-175.	0.6	45
141	Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5) Tj ETQq1 1 0.784314 rgBT /Overd cancer - NEOPANC. <i>BMC Cancer</i> , 2012, 12, 112.	1.1	12
142	Surveillance of Pancreatic Cancer Patients after Surgical Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 1670-1677.	0.7	56
143	Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 2045-2053.	0.7	96
144	Posttherapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 268-277.	2.0	81
145	Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 68-79.	0.9	98
146	Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. <i>Radiation Oncology</i> , 2013, 8, 27.	1.2	46
147	A multiinstitutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. <i>Cancer</i> , 2013, 119, 2692-2700.	2.0	168
148	Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. <i>Surgery</i> , 2013, 154, 1078-1086.	1.0	79
149	Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1095-1103.	5.1	198
150	Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. <i>Hpb</i> , 2013, 15, 716-723.	0.1	25
151	Follow-up after curative surgery for pancreatic ductal adenocarcinoma: Asymptomatic recurrence is associated with improved survival. <i>European Journal of Surgical Oncology</i> , 2013, 39, 559-566.	0.5	43
152	Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp<sup>âˆ’âˆ’</sup>/rag2<sup>âˆ’âˆ’</sup>mice. <i>Gut</i> , 2013, 62, 741-750.	6.1	48
153	Clinical necessity of the immunohistochemical reassessment of paraaortic lymph nodes in resected pancreatic ductal adenocarcinoma. <i>Oncology Letters</i> , 2013, 6, 1189-1194.	0.8	6

#	ARTICLE	IF	CITATIONS
154	Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1473.	3.8	1,447
155	MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. <i>Oncogenesis</i> , 2013, 2, e51-e51.	2.1	128
157	Abdominal and pancreatic motion correlation using 4D CT, 4D transponders, and a gating belt. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 13-24.	0.8	5
158	Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
159	Reâ€adapting T cells for cancer therapy: from mouse models to clinical trials. <i>Immunological Reviews</i> , 2014, 257, 145-164.	2.8	67
160	Adjuvant Radiotherapy and Lymph Node Status for Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 112-116.	0.6	29
161	Pulmonary Adenocarcinoma Occurring 5 Years after Resection of a Primary Pancreatic Adenocarcinoma: A Relevant Differential Diagnosis. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-4.	0.2	3
162	Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenetic Strategy. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	52
163	Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. <i>Hpb</i> , 2014, 16, 197-203.	0.1	27
164	Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: Is it worthwhile?. <i>Surgery</i> , 2014, 155, 58-66.	1.0	95
165	Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 659-665.	0.8	15
166	Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment. <i>Brain, Behavior, and Immunity</i> , 2014, 40, 40-47.	2.0	192
167	Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. <i>Surgery</i> , 2014, 156, 280-289.	1.0	61
168	Resection of metachronous pancreatic cancer 4Âyears after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 290.	0.8	6
169	Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 717-726.	0.9	6
170	Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma. <i>Digestive Surgery</i> , 2015, 32, 464-471.	0.6	37
171	Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 973-978.	0.8	26
172	Poor prognosis of common-type invasive ductal carcinomas that originate in the branching pancreatic duct. <i>Surgery Today</i> , 2015, 45, 1291-1298.	0.7	1

#	ARTICLE	IF	CITATIONS
173	Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. <i>Experimental Cell Research</i> , 2015, 336, 119-129.	1.2	45
175	Personalized medicine in pancreatic cancer: the revolution has begun. <i>Personalized Medicine</i> , 2015, 12, 515-523.	0.8	1
177	Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 3985-3992.	1.0	19
178	Pancreatic Cancer: 80 Years of Surgeryâ€™Percentage and Repetitions. <i>HPB Surgery</i> , 2016, 2016, 1-15.	2.2	16
179	Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. <i>Journal of Cancer</i> , 2016, 7, 283-288.	1.2	52
180	Microscopic Residual Tumor After Pancreaticoduodenectomy. <i>Pancreas</i> , 2016, 45, 748-754.	0.5	3
181	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2016, 264, 1073-1081.	2.1	131
182	Meta-analysis of benefits of portalâ€™superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. <i>British Journal of Surgery</i> , 2016, 103, 179-191.	0.1	153
183	Treatment of Recurrent Pancreatic Cancer After Surgery`. , 2016, , 1-26.		0
184	The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomographyâ€™computed tomography (PETâ€™CT) in follow-up of curatively resected pancreatic cancer patients. <i>Hpb</i> , 2016, 18, 57-64.	0.1	27
185	Macrophage-secreted granulins supports pancreatic cancer metastasis by inducing liver fibrosis. <i>Nature Cell Biology</i> , 2016, 18, 549-560.	4.6	329
186	Fibroblasts form a hospitable metastatic niche in the liver. <i>Nature Cell Biology</i> , 2016, 18, 465-466.	4.6	6
187	Does finding early recurrence improve outcomes, and at what cost?. <i>Journal of Surgical Oncology</i> , 2016, 114, 329-335.	0.8	5
188	Initial experience in sentinel lymph node detection in pancreatic cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 287-291.	0.1	0
189	Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. <i>Pancreatology</i> , 2016, 16, 1124-1128.	0.5	18
190	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 320-337.	1.0	21
191	Pancreatic cancer chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 617-628.	1.0	11
192	Surgical margins for duodenopancreatectomy. <i>Updates in Surgery</i> , 2016, 68, 279-285.	0.9	1

#	ARTICLE	IF	CITATIONS
193	Examination of resection for pulmonary metastasis of pancreatic cancer. <i>The Journal of the Japanese Association for Chest Surgery</i> , 2016, 30, 540-544.	0.0	0
194	Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer. <i>Medicine (United States)</i> , 2016, 95, e4191.	0.4	6
195	Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 831-839.	0.9	8
196	Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 561-570.	0.4	12
197	Initial experience in sentinel lymph node detection in pancreatic cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 287-291.	0.0	3
198	Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 286-298.	2.0	44
199	Original Scientific Reports: Clinicopathological Findings of Remnant Pancreatic Cancers in Survivors Following Curative Resections of Pancreatic Cancers. <i>World Journal of Surgery</i> , 2016, 40, 974-981.	0.8	21
200	Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 42-46.	0.6	5
201	Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. <i>Hpb</i> , 2017, 19, 83-92.	0.1	74
202	The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma – A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2017, 26, 105-115.	0.8	92
203	Preventing intrahepatic infection after ablation of liver tumours in biliary-enteric anastomosis patients. <i>International Journal of Hyperthermia</i> , 2017, 33, 664-669.	1.1	4
205	Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 426-433.	1.4	37
206	Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3674-3682.	0.7	29
207	Aggressive venous invasion in the area of carcinoma correlates with liver metastasis as an index of metastasis for invasive ductal carcinoma of the pancreas. <i>Pancreatology</i> , 2017, 17, 951-955.	0.5	8
208	Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. <i>Pancreatology</i> , 2017, 17, 773-781.	0.5	14
209	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. <i>Pancreas</i> , 2017, 46, 994-1002.	0.5	21
210	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2681-2690.	3.2	91
211	Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. <i>Biomarker Insights</i> , 2017, 12, 117727191771544.	1.0	16

#	ARTICLE	IF	CITATIONS
212	Stent patency in patients with distal malignant biliary obstruction receiving chemo(radio)therapy. <i>Endoscopy International Open</i> , 2017, 05, E1035-E1043.	0.9	7
213	Do the well known prognostic parameters in pancreatic ductal adenocarcinoma really reflect survival?. <i>Turk Patoloji Dergisi</i> , 2017, 34, 127-133.	0.1	1
214	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. <i>PLoS ONE</i> , 2017, 12, e0186341.	1.1	15
215	Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreateoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 194.	0.4	2
216	Major pancreatic resections: normal postoperative findings and complications. <i>Insights Into Imaging</i> , 2018, 9, 173-187.	1.6	27
218	CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1415-1425.	3.2	73
219	Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. <i>BJS Open</i> , 2018, 2, 52-61.	0.7	29
220	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
221	Adjuvant Chemoradiation Therapy for Pancreatic Cancer. , 2018, , 1073-1088.		0
222	Treatment of Recurrent Pancreatic Cancer After Surgery. , 2018, , 1105-1130.		0
223	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. <i>Digestion</i> , 2018, 98, 69-74.	1.2	5
224	Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1834-1835.	2.4	1
225	Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. <i>Journal of Surgical Research</i> , 2018, 221, 152-160.	0.8	27
226	Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. <i>Abdominal Radiology</i> , 2018, 43, 505-513.	1.0	15
227	The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1368603.	2.1	33
228	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. <i>Annals of Surgical Oncology</i> , 2018, 25, 280-289.	0.7	31
229	Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma. <i>Clinical Journal of Gastroenterology</i> , 2018, 11, 53-61.	0.4	6
230	Role of rapid kV-switching dual-energy CT in assessment of post-surgical local recurrence of pancreatic adenocarcinoma. <i>Abdominal Radiology</i> , 2018, 43, 497-504.	1.0	11

#	ARTICLE	IF	CITATIONS
231	Enhanced Electric Pulse Technology for the Ablation of Pancreatic Cancer. , 2018, , .		2
232	Recent advances in radiation therapy of pancreatic cancer. F1000Research, 2018, 7, 1931.	0.8	12
233	Prospective Follow-up Study of the Recurrence of Pancreatic Cancer Diagnosed at an Early Stage. Pancreas, 2018, 47, 482-488.	0.5	13
234	The Combination of Neutrophilâ€™toâ€™lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer. Anticancer Research, 2018, 38, 5497-5503.	0.5	10
235	Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Research, 2018, 78, 4253-4269.	0.4	105
236	Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing. DNA and Cell Biology, 2018, 37, 839-849.	0.9	25
237	Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2018, 25, 2475-2483.	0.7	77
238	Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Annals of the Royal College of Surgeons of England, 2019, 101, 453-462.	0.3	33
239	Surgery for Recurrent Pancreatic Cancer: Is It Effective?. Cancers, 2019, 11, 991.	1.7	45
240	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Modern Pathology, 2019, 32, 844-854.	2.9	4
241	Postoperative surveillance of pancreatic cancer patients. European Journal of Surgical Oncology, 2019, 45, 1770-1777.	0.5	32
242	Identification of key pathways and genes changes in pancreatic cancer cells (BXPC-3) after cross-talk with primary pancreatic stellate cells using bioinformatics analysis. Neoplasma, 2019, 66, 681-693.	0.7	7
243	The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Cancers, 2019, 11, 745.	1.7	12
244	Management of isolated recurrence after surgery for pancreatic adenocarcinoma. British Journal of Surgery, 2019, 106, 898-909.	0.1	41
245	Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scandinavian Journal of Gastroenterology, 2019, 54, 780-786.	0.6	17
246	A new delineation method research of the clinical target volume for pancreatic cancer adjuvant radiotherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 201-208.	0.6	2
247	Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. EBioMedicine, 2019, 43, 282-294.	2.7	43
248	Decreased serum carbohydrate antigen 19â€™9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer, 2019, 19, 252.	1.1	57

#	ARTICLE	IF	CITATIONS
249	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.	3.2	78
250	Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. <i>BMJ Open</i> , 2019, 9, e028696.	0.8	3
251	A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. <i>Frontiers in Oncology</i> , 2019, 9, 1197.	1.3	12
252	Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 810-820.	3.3	15
253	Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 50-54.	0.3	5
254	The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible?. <i>Academic Radiology</i> , 2019, 26, 775-781.	1.3	16
255	Clinical Outcome of Resected Remnant Pancreatic Cancer After Resection of the Primary Pancreatic Cancer. <i>Journal of Investigative Surgery</i> , 2019, 32, 670-678.	0.6	2
256	High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neoplasms. <i>Surgery Today</i> , 2020, 50, 832-840.	0.7	4
257	Clinical anatomy of the anterior and posterior hepatic plexuses, including relations with the pancreatic plexus: A cadaver study. <i>Clinical Anatomy</i> , 2020, 33, 630-636.	1.5	12
258	Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2907-2913.	1.1	5
259	Plant-derived saccharides and their inhibitory potential on metastasis associated cellular processes of pancreatic ductal adenocarcinoma cells. <i>Carbohydrate Research</i> , 2020, 490, 107903.	1.1	4
260	A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). <i>Hpb</i> , 2020, 22, 649-659.	0.1	15
261	Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2020, 20, 1472-1478.	0.5	8
262	Metastases or primary recurrence to the lung is related to improved survival of pancreatic cancer as compared to other sites of dissemination. Results of a systematic review with meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1789-1794.	0.5	13
263	Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer?. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 448-454.	1.2	4
264	Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications. <i>Pancreatology</i> , 2020, 20, 1486-1494.	0.5	5
265	Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. <i>Pancreas</i> , 2020, 49, e75-e76.	0.5	2
266	Genetic Variants, Fat Malabsorption, and Ancestral Background in a Small Chronic Pancreatitis Cohort. <i>Pancreas</i> , 2020, 49, e76-e78.	0.5	0

#	ARTICLE	IF	CITATIONS
267	Three Curative Pancreatectomies for the Metachronous Appearance of Pancreatic Invasive Ductal Adenocarcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 392-397.	0.3	0
268	Optimal timing and treatment strategy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 457-468.	0.8	21
269	Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. <i>EBioMedicine</i> , 2020, 53, 102662.	2.7	33
270	The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. <i>Surgery Today</i> , 2020, 50, 335-343.	0.7	11
271	Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle aspiration followed by pancreatectomy: a case report and literature review. <i>BMC Gastroenterology</i> , 2020, 20, 13.	0.8	26
272	Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. <i>Surgery</i> , 2021, 169, 649-654.	1.0	25
273	Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. <i>Cancer Letters</i> , 2021, 497, 1-13.	3.2	65
274	The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospective Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 3171-3183.	0.7	6
275	Chemoradiotherapy after curative surgery for locally advanced pancreatic cancer: A 20-year single center experience. <i>Surgical Oncology</i> , 2021, 36, 36-41.	0.8	7
276	Pattern of local recurrence after curative resection in pancreatic ductal adenocarcinoma according to the initial location of the tumor. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 105-114.	1.4	12
277	Patterns of Recurrence After Surgery for Pancreatic Cancer. , 2021, , 1153-1168.		1
278	Robotic gastrointestinal surgery: learning curve, educational programs and outcomes. <i>Updates in Surgery</i> , 2021, 73, 799-814.	0.9	12
279	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1301, 7-24.	0.8	1
280	The Role of Pathological Method and Clearance Definition for the Evaluation of Margin Status after Pancreatoduodenectomy for Periapillary Cancer. Results of a Multicenter Prospective Randomized Trial. <i>Cancers</i> , 2021, 13, 2097.	1.7	6
281	Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 2285.	1.7	16
282	Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. <i>Pancreatology</i> , 2021, 21, 787-795.	0.5	15
283	Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer. <i>Nuclear Medicine Communications</i> , 2021, 42, 1112-1121.	0.5	3
284	Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 714718.	1.8	0



#	ARTICLE	IF	CITATIONS
285	Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery Open</i> , 2021, 2, e096.	0.7	1
286	Adjuvant Radiotherapy in Patients With Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature. <i>Anticancer Research</i> , 2021, 41, 4697-4704.	0.5	6
287	Preoperative CTC-Detection by CellSearch® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 485.	1.7	18
288	Longitudinal analysis of cell-free mutated KRAS and CA 19â€“9 predicts survival following curative resection of pancreatic cancer. <i>BMC Cancer</i> , 2021, 21, 49.	1.1	19
289	Molecular Biology of Peritoneal Carcinomatosis. , 2007, 134, 21-33.		61
290	Total Pancreatectomy for Treatment of Pancreatic Adenocarcinoma. , 2008, , 329-339.		1
291	Adjuvant Chemotherapy in Pancreatic Cancer. , 2010, , 1051-1077.		2
292	Adjuvant Therapy for Pancreatic Cancer. <i>Recent Results in Cancer Research</i> , 2012, 196, 65-88.	1.8	22
293	Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 936-945.	2.1	425
295	Expression of CAMK1 and its association with clinicopathologic characteristics in pancreatic cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1198-1206.	1.6	24
296	Metastatic pancreatic cancer presenting as linitis plastica of the stomach. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015214298.	0.2	2
297	Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. <i>Surgical Case Reports</i> , 2020, 6, 309.	0.2	5
298	Carcinoembryonic Antigen-Related Cell Adhesion Molecules (CEACAM) 1, 5 and 6 as Biomarkers in Pancreatic Cancer. <i>PLoS ONE</i> , 2014, 9, e113023.	1.1	76
299	Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0171985.	1.1	25
300	PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-Î²B pathway. <i>Oncotarget</i> , 2017, 8, 86488-86502.	0.8	22
301	Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. <i>Oncotarget</i> , 2018, 9, 31771-31786.	0.8	19
302	Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. <i>Oncotarget</i> , 2015, 6, 36903-36910.	0.8	62
303	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. <i>Oncotarget</i> , 2016, 7, 35159-35168.	0.8	14

#	ARTICLE	IF	CITATIONS
304	A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. <i>Oncotarget</i> , 2016, 7, 44299-44309.	0.8	13
305	Total mesopancreas excision for pancreatic head cancer: analysis of 120 cases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 423-428.	0.7	18
306	Pancreatic Cancer Metastasis: Are we being Pre-EMT?. <i>Current Pharmaceutical Design</i> , 2015, 21, 1249-1255.	0.9	48
307	Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma. <i>Korean Journal of Radiology</i> , 2020, 21, 316.	1.5	18
308	Adjuvant therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2001, 7, 482.	1.4	18
309	A CASE OF LUNG METASTASIS OCCURRING 6 YEARS AFTER PANCREATICODUODENECTOMY FOR PANCREAS CANCER. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2010, 71, 1034-1038.	0.0	7
310	A CASE OF RECURRENT PANCREATIC DUCTAL ADENOCARCINOMA IN THE REMAINING PANCREATIC HEAD. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2011, 72, 1261-1265.	0.0	3
311	Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 343-51.	0.6	55
312	Sarcoma metastasis to the pancreas: experience at a single institution. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 220-227.	0.4	7
313	Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 109.	0.8	31
314	Multimodality treatment of recurrent pancreatic cancer: Mith or reality?. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 375.	0.8	15
315	Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis. <i>Gut and Liver</i> , 2014, 8, 557-562.	1.4	5
316	Metastatic Lung Cancer Operable 52 Months after Distal Pancreatectomy for Pancreatic Cancer. <i>Japanese Journal of Gastroenterological Surgery</i> , 2014, 47, 196-202.	0.0	1
317	Successful Surgical Resection of a Lung Metastasis Originating from Pancreatic Cancer. <i>Japanese Journal of Gastroenterological Surgery</i> , 2014, 47, 132-138.	0.0	3
318	Influence of Perineural Invasion on Survival and Recurrence in Patients with Resected Pancreatic Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5133-5139.	0.5	34
319	Regional Chemotherapy of Cancer of the Pancreas. , 2000, , 101-125.		0
320	Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreas cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4234-4234.	0.8	0
321	Analysis of autopsy findings in long-term survivors after surgical resection for invasive ductal carcinoma of the pancreas. <i>Suizo</i> , 2007, 22, 130-136.	0.1	9

#	ARTICLE	IF	CITATIONS
322	Adjuvant Chemoradiation for Pancreatic Cancer: Past, Present and Future. , 2008, , 535-547.		0
323	Efficacy of Adjuvant Chemotherapy with Gemcitabine after Resection of Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2009, 42, 347-354.	0.0	0
324	Lymphadenektomie in der Pankreaschirurgie. , 2010, , 291-295.		0
325	A CASE OF SOLITARY METASTATIC GASTRIC CANCER FROM PANCREATIC HEAD CANCER AFTER PANCREATICOUDUENECTOMY. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq1 1 0.784314rgBT /Overlock 10T		0
326	Spezielle Situationen und taktische Vorgehensweise. , 2010, , 296-301.		0
327	Adjuvant Chemoradiation Therapy for Pancreatic Cancer. , 2010, , 1079-1092.		0
328	A Case of Metachronous Pancreatic Carcinoma with No Recurrence for 6 Years after Pancreatectomy. Japanese Journal of Gastroenterological Surgery, 2012, 45, 304-311.	0.0	2
329	Long-term survivor of stage IVb pancreatic cancer with peritoneal dissemination treated with neoadjuvant chemoradiotherapy followed by pancreaticoduodenectomy. Suizo, 2012, 27, 62-68.	0.1	0
331	Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe. , 2013, , 129-143.		0
332	Diagnostik und Therapie beim Rezidiv des Pankreaskarzinoms. , 2013, , 406-407.		0
333	New trends in gastrointestinal surgical oncology. Cancer Treatment and Research, 1998, 98, 239-291.	0.2	0
334	Liver Metastases from Pancreatic Adenocarcinoma. , 2015, , 95-109.		0
335	Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer.. Journal of Clinical Oncology, 2015, 33, 451-451.	0.8	0
336	Solitary pulmonary metastasis of pancreatic cancer presenting a thin-walled cavity. International Journal of Cancer Therapy and Oncology, 2015, 3, 338.	0.2	0
337	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0
338	Three Cases of Lung Metastases from Pancreatic Cancer Performed Lung Resection. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 1062-1068.	0.0	1
339	Characteristics of Small Pancreatic Carcinoma: Neural Invasion is Associated with Tumor Recurrence. Journal of Cancer Therapy, 2017, 08, 1125-1134.	0.1	0
340	Adjuvant Chemoradiation Therapy for Pancreatic Cancer. , 2017, , 1-16.		0

#	ARTICLE	IF	CITATIONS
341	Mesenteric Approach for Pancreaticoduodenectomy. , 2017, , 201-206.		0
342	A Resected Case of Lung Metastasis from Pancreatic Cancer in which Preoperative Ultrasound-Guided Needle Biopsy was Useful for Limited Surgery. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784304 rgBT dOverloc		
343	The role of radiation for pancreatic adenocarcinoma. Journal of Pancreatology, 2020, 3, 72-80.	0.3	6
344	Pancreatic Cancer“Are There New Treatment Options?. , 2006, 574, 107-110.		0
346	Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 1423-1435.	0.8	6
347	Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2021, 10, 5784.	1.0	1
348	The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets. Biomolecules, 2022, 12, 152.	1.8	19
349	Endoscopic approach in the diagnosis of high-grade pancreatic intraepithelial neoplasia. Digestive Endoscopy, 2022, 34, 927-937.	1.3	13
350	Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection. Technology in Cancer Research and Treatment, 2022, 21, 153303382210784.	0.8	1
351	Potentially curative resection of an abdominal wall metastasis from pancreatic adenocarcinoma: a case report. Journal of Surgical Case Reports, 2022, 2022, rjac138.	0.2	1
352	Impact of the aberrant right hepatic artery on local recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Surgery, 2022, 172, 691-699.	1.0	4
355	Management of Cancer Recurrence. , 0, , 772-775.		0
356	The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma. BMC Cancer, 2022, 22, 463.	1.1	3
357	Current Pathology Model of Pancreatic Cancer. Cancers, 2022, 14, 2321.	1.7	9
359	A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma. Medical Science Monitor, 0, 28, .	0.5	1
360	Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology, 2022, 22, 741-748.	0.5	8
361	Peritumoral abnormalities on dynamic-enhanced CT after brachytherapy for hepatic malignancies: local progression or benign changes?. European Radiology, 0, , .	2.3	0
363	Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. Journal of Investigative Surgery, 2023, 36, .	0.6	54

#	ARTICLE	IF	CITATIONS
364	A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). <i>Trials</i> , 2022, 23, .	0.7	4